GHC Summit at Harvard Medical School Announces Cannabis Science as Industry Partner in the Launch of the International Phytomedicines Institute at Harvard Medical School
31. Mai 2019 09:06 ET
|
Cannabis Science, Inc.
IRVINE, CA, May 31, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Cannabis Science, Inc. (OTC: CBIS), a U.S. company specializing in the research and development of cannabinoid-based medicines, is...
Cannabis Science Set to Participate in the Premier Event Focused on High-Impact Global Collaborations; The Global Health Catalyst Summit at Harvard Medical School Starts Today
24. Mai 2019 07:53 ET
|
Cannabis Science, Inc.
IRVINE, CA, May 24, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Cannabis Science, Inc. (OTC: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, is pleased to...
Cannabis Science Announces NFL Greats Past and Present Set to Participate and Partner With the Global Health Catalyst Summit at Harvard Medical School on May 24-26, 2019
23. Mai 2019 12:46 ET
|
Cannabis Science, Inc.
IRVINE, CA, May 23, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Cannabis Science, Inc. (OTC: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, is pleased to...
Cannabis Science and Dana-Farber Cancer Institute Sign a New Research Agreement to Investigate Proprietary Extract From Justicia Plant
20. Mai 2019 11:28 ET
|
Cannabis Science, Inc.
IRVINE, CA, May 20, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Cannabis Science, Inc. (OTC: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, has entered into a...
Cannabis Science Releases Clinical Drug-Development Pipeline as it Transitions Into Clinical Trials; Right on Time for the Upcoming Global Health Catalyst Summit at Harvard Medical School, May 24-26, 2019
10. Mai 2019 07:30 ET
|
Cannabis Science, Inc.
IRVINE, CA, May 10, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Cannabis Science, Inc. (OTC: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, hits inflection...
Independent Valuation of U.S. Patent Number 9,763,991 for Cannabinol (CBN) Initiated as Cannabis Science Negotiates Licensing and Marketing Deals in Canada and the USA to Develop and Sell CBN Products Utilizing the Company’s Patent
15. April 2019 07:33 ET
|
Cannabis Science, Inc.
Cannabis Science’ CBN Patent is for the Treatment of Neurological Conditions, Including Sleep Deprivation, Anxiety, PTSD, and More IRVINE, CA, April 15, 2019 (GLOBE NEWSWIRE) -- via...
Elpasso Farms Just Announced South African Health Products Regulatory Authority (SAHPRA) Awarded Elpasso Farms One of the First Medical Cannabis Cultivation Licenses; Cannabis Science Applauds
10. April 2019 08:53 ET
|
Cannabis Science, Inc.
IRVINE, CA, April 10, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Cannabis Science, Inc. (OTC: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, is pleased to...
Cannabis Science Expands Into Canadian Market With Wholly-Owned Subsidiary Cannabis Science Canada Inc., Commences Negotiations for Canadian Land, Licenses, and Expansion Capital
25. März 2019 08:47 ET
|
Cannabis Science, Inc.
IRVINE, CA, March 25, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Cannabis Science, Inc. (OTC: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, is pleased to...
Cannabis Science iCannabinoid Ambassadors Program Appointments Underway; Ambassadors Will Promote Company Initiatives Globally and Help Share Accurate and Reliable Health Information
15. März 2019 13:19 ET
|
Cannabis Science, Inc.
IRVINE, CA, March 15, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Cannabis Science, Inc. (OTC: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, announces that...
Cannabis Science Set to Integrate Its Sponsored Research In Nigeria to Include Its U.S. Patent Number 9,763,991 for Compositions of Cannabinol (CBN) for Treatment of Various Neurological Conditions
25. Februar 2019 07:28 ET
|
Cannabis Science, Inc.
IRVINE, CA, Feb. 25, 2019 (GLOBE NEWSWIRE) -- Pre-Clinical Work and Animal Studies Underway, and Protocols for Clinical Studies Under Development via NEWMEDIAWIRE -- Cannabis Science, Inc....